Pharmacogenomics education and research at the Department of Pharmacy, University of Patras, Greece

References

• 1 Borg J, Phylactides M, Bartsakoulia M et al. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients. Pharmacogenomics 13(13), 1487–1500 (2012).
  CASGoogle Scholar
• 2 Tafrali C, Paizi A, Borg J, Radmilovic M et al. Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy. Pharmacogenomics 14(5), 469–483 (2013).
  CASGoogle Scholar
• 3 Gravia A, Chondrou V, Sgourou A et al. Individualizing fetal hemoglobin augmenting therapy for β-type hemoglobinopathies patients. Pharmacogenomics 15(10), 1355–1364 (2014).
  CASGoogle Scholar
• 4 Chalikiopoulou C, Tavianatou AG, Sgourou A et al. Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients. Pharmacogenomics 17(4), 393–403 (2016).
  CASGoogle Scholar
• 5 Gravia A, Chondrou V, Kolliopoulou A et al. Correlation of SIN3A genomic variants with β-hemoglobinopathies disease severity and hydroxyurea treatment efficacy. Pharmacogenomics (2016) (In Press).
  Google Scholar
• 6 Borg J, Papadopoulos P, Georgitsi M et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat. Genet. 42(9), 801–805 (2010).
  Medline CASGoogle Scholar
• 7 Zukic B, Radmilovic M, Stojiljkovic M et al. Functional analysis of the role of TPMT gene promoter VNTR polymorphism in TPMT gene transcription. Pharmacogenomics 11(4), 547–557 (2010).
  CASGoogle Scholar
• 8 Kotur N, Stankovic B, Kassela K et al. Six-mercaptopurine influences TPMT gene transcription in a TPMT gene promoter variable number of tandem repeats-dependent manner. Pharmacogenomics 13(3), 283–295 (2012).
  CASGoogle Scholar
• 9 Kotur N, Dokmanovic L, Janic D et al. TPMT gene expression is increased during maintenance therapy in childhood acute lymphoblastic leukemia patients in a TPMT gene promoter variable number of tandem repeat-dependent manner. Pharmacogenomics 16(15), 1701–1712 (2015).
  CASGoogle Scholar
• 10 Squassina A, Manchia M, Borg J et al. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics 12(11), 1559–1569 (2011).
  CASGoogle Scholar
• 11 Mizzi C, Mitropoulou C, Mitropoulos K et al. Personalized pharmacogenomics profiling using whole genome sequencing. Pharmacogenomics 15(9), 1223–1234 (2014).
  CASGoogle Scholar
• 12 Katsila T, Konstantinou E, Lavda I et al. Pharmacometabolomics-aided pharmacogenomics in autoimmune disease. EBioMedicine 5, 40–45 (2016).
  MedlineGoogle Scholar
• 13 The Golden Helix Foundation. www.goldenhelix.org.
  Google Scholar
• 14 Mizzi C, Dalabira E, Kumuthini J et al. A European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics. PLoS ONE 11(9), e0162866 (2016).
  MedlineGoogle Scholar
• 15 Mette L, Mitropoulos K, Vozikis A, Patrinos GP. Pharmacogenomics and public health: implementing populationalized medicine. Pharmacogenomics 13(7), 803–813 (2012).
  CASGoogle Scholar
• 16 FINDbase Worldwide database of clinically relevant genomic variation allele frequencies. www.findbase.org.
  Google Scholar
• 17 Georgitsi M, Viennas E, Gkantouna V et al. Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase. Pharmacogenomics 12(1), 49–58 (2011).
  CASGoogle Scholar
• 18 Papadopoulos P, Viennas E, Gkantouna V et al. Developments in FINDbase worldwide database for clinically relevant genomic variation allele frequencies. Nucleic Acids Res. 42, D1020–D1026 (2014).
  Medline CASGoogle Scholar
• 19 DruGeVar database. http://drugevar.genomicmedicinealliance.org.
  Google Scholar
• 20 Potamias G, Lakiotaki K, Katsila T et al. Deciphering next-generation pharmacogenomics: an information technology perspective. OPEN Biol. 4(7), 140071 (2014).
  MedlineGoogle Scholar
• 21 Lakiotaki K, Kartsaki E, Kanterakis A, Katsila T, Patrinos GP, Potamias G. ePGA: a web-based information system for translational pharmacogenomics. PLoS ONE 11(9), e0162801 (2016).
  MedlineGoogle Scholar
• 22 US Food and Drug Administration. www.fda.gov.
  Google Scholar
• 23 European Medicines Agency. www.ema.europa.eu.
  Google Scholar
• 24 Electronic PharmacoGenomics Assistant. www.epga.gr.
  Google Scholar
• 25 Dalabira E, Komianou A, Daki E et al. An online resource triangulating drugs with genes and biomarkers for clinical pharmacogenomics. Public Health Genomics 17(5–6), 265–271 (2014).
  MedlineGoogle Scholar
• 26 RD-Connect. www.rd-connect.eu.
  Google Scholar
• 27 Kampourakis K, Vayena E, Mitropoulou C et al. Key challenges for next generation pharmacogenomics. EMBO Rep. 15(5), 472–476 (2014).
  Medline CASGoogle Scholar
• 28 Sagia A, Cooper DN, Poulas K, Stathakopoulos V, Patrinos GP. A critical appraisal of the private genetic and pharmacogenomic testing environment in Greece. Pers. Med. 8(4), 413–420 (2011).
  Google Scholar
• 29 Mai Y, Koromila T, Sagia A et al. A critical view of the general public's awareness and physicians’ opinion of the trends and potential pitfalls of genetic testing in Greece. Pers. Med. 8(5), 551–561 (2011).
  Google Scholar
• 30 Mai Y, Mitropoulou C, Papadopoulou XE et al. Critical appraisal of the views of healthcare professionals with respect to pharmacogenomics and personalized medicine in Greece. Pers. Med. 11(1), 15–26 (2014).
  Google Scholar
• 31 Mitropoulou C, Mai Y, van Schaik RH, Vozikis A, Patrinos GP. Documentation and analysis of the policy environment and key stakeholders in pharmacogenomics and genomic medicine in Greece. Public Health Genomics 17(5–6), 280–286 (2014).
  MedlineGoogle Scholar
• 32 Patrinos GP, Baker DJ, Al-Mulla F, Vasiliou V, Cooper DN. Genetic tests obtainable through pharmacies: the good, the bad and the ugly. Hum. Genomics 7(1), 17 (2013).
  MedlineGoogle Scholar
• 33 Pisanu C, Tsermpini EE, Mavroidi E, Katsila T, Patrinos GP, Squassina A. Assessment of the pharmacogenomics educational environment in southeast Europe. Public Health Genomics 17(5–6), 272–279 (2014).
  MedlineGoogle Scholar
• 34 Mitropoulou C, Fragoulakis V, Bozina N et al. Economic evaluation for pharmacogenomic-guided warfarin treatment for elderly Croatian patients with atrial fibrillation. Pharmacogenomics 16(2), 137–148 (2015).
  CASGoogle Scholar
• 35 Mitropoulou C, Fragoulakis V, Rakicevic LB et al. Economic analysis of pharmacogenomic-guided clopidogrel treatment in Serbian patients with myocardial infarction undergoing primary percutaneous coronary intervention. Pharmacogenomics (2016) (In Press).
  Google Scholar
• 36 Fragoulakis V, Mitropoulou C, van Schaik RH, Maniadakis N, Patrinos GP. An alternative methodological approach for cost–effectiveness analysis and decision making in genomic medicine. OMICS 20(5), 274–282 (2016).
  Medline CASGoogle Scholar
• 37 Ubiquitous Pharmacogenomics. www.upgx.eu.
  Google Scholar
• 38 National Academy of Sciences of the USA – Global Genomic Medicine Collaborative. www.nationalacademies.org/hmd/Activities/Research/GenomicBasedResearch/Innovation-Collaboratives/Global_Genomic_Medicine_Collaborative.aspx.
  Google Scholar
• 39 Manolio TA, Abramowicz M, Al-Mulla F et al. Global implementation of genomic medicine: we are not alone. Sci. Transl. Med. 7(290), 290ps13 (2015).
  MedlineGoogle Scholar
• 40 Genomic Medicine Alliance. www.genomicmedicinealliance.org.
  Google Scholar
• 41 Cooper DN, Brand A, Dolzan V et al. Bridging genomics research between developed and developing countries: the Genomic Medicine Alliance. Pers. Med. 11(7), 615–623 (2014).
  CASGoogle Scholar
• 42 European Medicines Agency; CHMP Pharmacogenomics Working Party. www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CHMP/people_listing_000018.jsp&mid=WC0b01ac0580028d91.
  Google Scholar
• 43 Squassina A, Artac M, Manolopoulos VG et al. Translation of genetic knowledge into clinical practice: the expectations and realities of pharmacogenomics and personalized medicine. Pharmacogenomics 11(8), 1149–1167 (2010).
  Google Scholar
• 44 van der Wouden CH, Swen JJ, Samwald M, Mitropoulou C, Schwab M, Guchelaar HJ. On behalf of the Ubiquitous-Pharmacogenomics Consortium. A brighter future for the implementation of pharmacogenomic testing. Eur. J. Hum. Genet. doi:10.1038/ejhg.2016.116 (2016) (Epub ahead of print).
  MedlineGoogle Scholar